122 related articles for article (PubMed ID: 10551482)
1. Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma.
De Winter F; Brans B; Van De Wiele C; Dierckx RA
Clin Nucl Med; 1999 Nov; 24(11):898-9. PubMed ID: 10551482
[No Abstract] [Full Text] [Related]
2. Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
Liepe K; Kropp J; Hliscs R; Franke WG
Clin Nucl Med; 2000 Nov; 25(11):901-4. PubMed ID: 11079588
[TBL] [Abstract][Full Text] [Related]
3. [Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP].
Hauswirth AE; Palmedo H; Dierke-Dzierzon C; Biersack HJ; Krebs D
Zentralbl Gynakol; 1998; 120(2):83-6. PubMed ID: 9531713
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
Liepe K; Kropp J; Runge R; Kotzerke J
Br J Cancer; 2003 Aug; 89(4):625-9. PubMed ID: 12915868
[TBL] [Abstract][Full Text] [Related]
5. [Advanced prostate carcinoma: systemic radionuclide therapy of bone metastasis with rhenium-168-hydroxyethylidine diphosphonate].
Lerch H
Strahlenther Onkol; 1998 Jul; 174(7):384-5. PubMed ID: 9689963
[No Abstract] [Full Text] [Related]
6. [Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)].
Holle LH; Humke U; Trampert L; Ziegler M; Kirsch CM; Oberhausen E
Urologe A; 1997 Nov; 36(6):540-7. PubMed ID: 9487590
[TBL] [Abstract][Full Text] [Related]
7. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
Klutmann S; Bohuslavizki KH
MMW Fortschr Med; 1999 Nov; 141(44):38-9. PubMed ID: 10912142
[TBL] [Abstract][Full Text] [Related]
8. Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results.
Schoeneich G; Palmedo H; Dierke-Dzierzon C; Müller SC; Biersack HJ
Scand J Urol Nephrol; 1997 Oct; 31(5):445-8. PubMed ID: 9406304
[TBL] [Abstract][Full Text] [Related]
9. Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
Scher HI; Curley T; Yeh S; Tong W; O'Moore PV; Larson S
Adv Exp Med Biol; 1992; 324():115-29. PubMed ID: 1283494
[No Abstract] [Full Text] [Related]
10. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer.
Limouris G; Shukla SK; Manetou A; Kouvaris I; Plataniotis G; Triantafyllou N; Rigas AV; Vlahos L
Anticancer Res; 1997; 17(3B):1699-704. PubMed ID: 9179222
[TBL] [Abstract][Full Text] [Related]
11. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
Palmedo H; Bender H; Schomburg A; Grünwald F; Schöneich G; Zamorra P; Reichmann K; Dierke-Dzierzon C; Mallmann P; Biersack HJ
Nuklearmedizin; 1996 Apr; 35(2):63-7. PubMed ID: 8721578
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
Liepe K; Franke WG; Kropp J; Koch R; Runge R; Hliscs R
Nuklearmedizin; 2000 Sep; 39(6):146-51. PubMed ID: 11057405
[TBL] [Abstract][Full Text] [Related]
13. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
Róka R; Séra T; Pajor L; Thurzó L; Láng J; Csernay L; Pávics L
Orv Hetil; 2000 May; 141(19):1019-23. PubMed ID: 10846424
[TBL] [Abstract][Full Text] [Related]
14. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
15. Gastric uptake during Re-186 HEDP bone scintigraphy.
Limouris GS; Skukla SK
Anticancer Res; 1997; 17(3B):1779-81. PubMed ID: 9179234
[TBL] [Abstract][Full Text] [Related]
16. Palliative therapy with rhenium-186-HEDP for bone metastases of breast cancer.
Guerra UP; Englaro E; Cattaruzzi E
Tumori; 1997; 83(2):560-2. PubMed ID: 9226021
[No Abstract] [Full Text] [Related]
17. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP
Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
[TBL] [Abstract][Full Text] [Related]
18. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
de Klerk JM; Zonnenberg BA; Krouwer HG; Blijham GH; van Dijk A; van het Schip AD; van Die J; van Rijk PP
J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
[TBL] [Abstract][Full Text] [Related]
19. Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP.
Palmedo H; Grünwald F; Wagner U; Köhler S; Krebs D; Biersack HJ
Clin Nucl Med; 1998 Aug; 23(8):501-4. PubMed ID: 9712380
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
de Klerk JM; van Dijk A; van het Schip AD; Zonnenberg BA; van Rijk PP
J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
